MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.
Fiche publication
Date publication
avril 2016
Journal
Oncotarget
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry
Tous les auteurs :
Tabouret E, Bertucci F, Pierga JY, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, van Laere S, Ueno NT, Toiron Y, Finetti P, Birnbaum D, Borg JP, Viens P, Chinot O, Gonçalves A
Lien Pubmed
Résumé
Addition of bevacizumab to trastuzumab-based neoadjuvant chemotherapy in HER2-positive inflammatory breast cancer (IBC) was associated with favorable outcome in the BEVERLY-2 phase II trial. Circulating levels of matrix metalloproteinases (MMP) 2 and 9 were correlated to high response rate and prolonged survival in high-grade glioma treated with bevacizumab. We examined the prognostic impact of MMP2 and MMP9 serum levels in BEVERLY-2 patients.
Mots clés
Adult, Aged, Angiogenesis Inhibitors, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Bevacizumab, administration & dosage, Chemotherapy, Adjuvant, Female, Humans, Inflammatory Breast Neoplasms, drug therapy, Matrix Metalloproteinase 2, blood, Matrix Metalloproteinase 9, blood, Middle Aged, Neoadjuvant Therapy, Treatment Outcome
Référence
Oncotarget. 2016 Apr;7(14):18531-40